10x Genomics, Inc. (TXG) Stock Price & Analysis
10x Genomics, Inc. (TXG) fell 3.72% to USD 46.27 as of July 25, 2026 at 07:16 UTC, according to Nexqual real-time market data.
TXG last closed at USD 48.06; the session ranged USD 45.53–48.77 on volume of 2,671,644 shares. Market capitalization is $5.87B, with a 52-week range of USD 11.16–49.5 (NMS). Source: Nexqual, July 25, 2026 at 07:16 UTC.
Key Statistics (as of July 25, 2026 at 07:16 UTC)
| Price | USD 46.27 |
|---|---|
| Change | ▼ 3.72% (down) |
| Previous Close | USD 48.06 |
| Open | USD 48.58 |
| Day Range | USD 45.53 – 48.77 |
| 52-Week Range | USD 11.16 – 49.5 |
| Volume | 2,671,644 shares |
| Market Cap | $5.87B |
| Exchange | NMS |
Technical Analysis (TXG)
Nexqual's technical model rates TXG "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 07:16 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 64.86 (neutral) |
| vs SMA50 | Above (USD 34.02) |
| MACD | 3.77 (positive) |
Analyst Ratings (TXG)
Wall Street analysts rate TXG "Buy" based on 13 analysts, with a mean price target of USD 41.54 (range USD 25–50), per Nexqual as of July 25, 2026 at 07:16 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 41.54 |
| High Target | USD 50 |
| Low Target | USD 25 |
| Buy / Hold / Sell | 6 / 10 / 0 |
Earnings (TXG)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.02 |
| Revenue Estimate | $146.61M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.07 vs est -0.06 ▲ beat |
| 2025-12-31 | USD 0.07 vs est -0.04 ▲ beat |
| 2025-09-30 | USD -0.02 vs est -0.07 ▲ beat |
| 2025-06-30 | USD 0.48 vs est -0.08 ▲ beat |
Source: Nexqual, July 25, 2026 at 07:16 UTC.
Financials & Fundamentals (TXG)
| Total Revenue | $638.78M |
|---|---|
| Revenue Growth (YoY) | -2.60% |
| Gross Margin | +69.68% |
| Operating Margin | -11.30% |
| Profit Margin | -3.55% |
| ROE | -2.98% |
| Debt / Equity | 10 |
| Current Ratio | 5.9 |
| Total Cash | $539.85M |
| Total Debt | $81.39M |
| Free Cash Flow | $124.55M |
Source: Nexqual, July 25, 2026 at 07:16 UTC.
Financial Health Score (TXG)
Nexqual rates 10x Genomics, Inc.'s overall financial health "Solid" across five dimensions, as of July 25, 2026 at 07:16 UTC.
| Growth | Solid — Revenue +5% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 70%, operating -11% |
| Balance Sheet | Strong — $540M cash vs $81M debt, net cash position |
| Cash Flow | Strong — FCF $125M, 19% margin |
| Efficiency | Critical — ROE -3%, ROA -4.5% |
Ownership (TXG)
| Insider Ownership | +1.67% |
|---|---|
| Institutional Ownership | +112.08% |
| Shares Outstanding | 116.88M |
| Float | 114.79M |
| Short % of Float | +19.01% |
Source: Nexqual, July 25, 2026 at 07:16 UTC.
Leadership (TXG)
10x Genomics, Inc. is led by Serge Saxonov (age 48), Co-Founder, CEO & Director, per Nexqual as of July 25, 2026 at 07:16 UTC.
| Co-Founder, CEO & Director | Serge Saxonov (age 48) |
|---|---|
| Co-Founder, President, Chief Scientific Officer & Director | Benjamin J. Hindson (age 50) |
| CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer | Adam S. Taich (age 50) |
| Founding Scientist & CTO | Michael Schnall-Levin |
| Associate Director of Product Management | Jens Durruthy |
Major Backers & Investors (TXG)
Notable institutional backers of 10x Genomics, Inc. include ARK Invest, FMR, LLC, Quantinno Capital Management, LP, according to Nexqual as of July 25, 2026 at 07:16 UTC.
Active Investors
| Investor | Stake |
|---|---|
| ARK Invest | 17.06% |
| FMR, LLC | 15.18% |
| Quantinno Capital Management, LP | 4.63% |
| Fidelity | 4.63% |
| Sumitomo Mitsui Trust Group, Inc. | 4.37% |
| Amova Asset Management Americas Inc | 4.37% |
| Goldman Sachs | 3.4% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 17.24% |
| BlackRock | 10.93% |
| Geode Capital | 2.48% |
Source: Nexqual, July 25, 2026 at 07:16 UTC.
From 10x Genomics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-13)
Key Strengths & Strategy (as disclosed to the SEC)
- 10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
- The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits.
- It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample.
- This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TWST | Twist Bioscience Corporation | USD 90.27 | ▼ 4.18% |
| BEAM | Beam Therapeutics Inc. | USD 25.1 | ▼ 5.78% |
| PACB | Pacific Biosciences of Californ | USD 1.36 | ▼ 1.45% |
| VCYT | Veracyte, Inc. | USD 56.61 | ▼ 2.41% |
| GH | Guardant Health, Inc. | USD 147.33 | ▼ 2.27% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:16 UTC. This page is informational and not investment advice.